• PDF / 170,088 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 74 Downloads / 195 Views

DOWNLOAD

REPORT

---

1 S

Invasive squamous cell carcinoma of the head and neck: 5 case reports In a retrospective study of 1290 patients treated with doxorubicin-liposomal, 5 women aged 54–72 years were described, who developed invasive squamous cell carcinoma of the head and neck following treatment with doxorubicin-liposomal for ovarian or peritoneal cancer. The women, who had ovarian cancer (n=4) and peritoneal cancer (n=1) and who had been previously treated with unspecified regimens of chemotherapy, started receiving chemotherapy cycles of doxorubicin-liposomal [pegylated liposomal doxorubicin; dosages and routes not stated]. The patients received 16–47 cycles of doxorubicin-liposomal, with a cumulative dose of 640–1650 mg/m2. 7–70 months post-doxorubicin-liposomal therapy, the patients developed invasive squamous cell carcinoma of the head and neck, with stages T1N0M0 (n=2), T2N0M0 (n=2) and T2N3bM0 (n=1). Of these five women, two women developed head and neck cancers, while the doxorubicin-liposomal therapy was on-going. It was determined that the therapy with doxorubicin-liposomal might have increased the risk of head and neck cancers in these patients [not all times to reactions onsets stated]. Four of the five women underwent wide local excision, radical neck dissection after hospital admission or radiation therapy, while the remaining woman did not receive any treatment. Three of these women also received 3–5 unspecified regimens of chemotherapy after doxorubicin-liposomal. The outcomes of the invasive squamous cell carcinomas of the head and neck were noted to be no evidence of disease (n=2), local recurrence, partial mandibulectomy following hospital admission, followed by no evidence of disease (n=1), death with evidence of disease (n=1) and death with no evidence of disease (n=1) [causes of deaths not stated]. Rose PG, et al. Incidence of squamous cell carcinomas of the head and neck following prolonged pegylated liposomal doxorubicin. Anti-Cancer Drugs 31: 747-750, No. 7, 803517754 Aug 2020. Available from: URL: http://doi.org/10.1097/CAD.0000000000000950

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832